Research programme: phospholamban regulators - Edwards Lifesciences/Sangamo Therapeutics

Drug Profile

Research programme: phospholamban regulators - Edwards Lifesciences/Sangamo Therapeutics

Alternative Names: ZFP TF therapeutic angiogenesis programme - Sangamo; ZFP TFs for cardiovascular and vascular indications - Edwards Lifesciences/Sangamo

Latest Information Update: 11 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Edwards Lifesciences Corporation; Sangamo BioSciences
  • Class Gene therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Heart failure

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 21 Mar 2007 Preclinical development is ongoing
  • 22 Nov 2005 Preclinical data from a media release have been added to the Heart failure pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top